Looking for new stock investment opportunities might get you interested in cryptocurrencies, alternative payment methods, marijuana, and Artificial Intelligence companies, but there are other interesting areas to explore that could potentially make you a fortune as well.
Case in point Jeff Siegel’s “Magic Molecule” Companies and the promise of “quadruple-digit gains” with almost no risk involved. The author claims you’re “in a position to make quadruple, quintuple-digit gains on what scientists are calling the most important discovery in half a century” but are these claims even close to reality?
The investment opportunity is something called magic molecule stocks or, in other words, a medicine “made up of just one molecule” that promises to be a game-changer and cure some of the 21st century’s most common syndromes and diseases, including alcoholism, opioid addiction, depression, and PTSD.
According to the author’s claims, the medicine promoted is “plant-based and naturally occurring in our environment” with little to no side effects. Siegel is talking about a kind of hallucinogenics that “enable the body’s most powerful organ to do the healing: the mind”.
Similar to belladonna, ayahuasca, mescaline, and psilocybin, the promoted hallucinogen has been tested to some degree by decades and showed promising results in treating patients with mild and severe forms of depression, anxiety, PTSD, and opioid addiction.
Psychedelic drugs, whether natural or chemically invented and enhanced (MDMA and LSD) have suffered from major backlash back in the 1960’s and carried the stigma for decades, while keeping research in the field limited.
Siegel claims that more and more Big Pharma companies are “starting to come out with magic molecule-based treatments, including a nasal spray from Johnson & Johnson”, calling it “cannabis 2.0”. With FDA on board with redeeming these substances as “safe for consumption”, the stock market is most likely to increase fast in the next years.
So, what exactly is Siegel advertising? A yearly subscription to his newsletter and various bonus reports on which companies to invest in so that you can get a slice of a worldwide market that the author believes will get to “$2 trillion a year”. You can read more of his ultra-optimistic claims by subscribing to the newsletter Green Chip Stocks for $99 per 12 months or $179 per 24 months.
Apart from the investment opportunities in small psychedelic drug companies that will potentially become big players in the next few years, you’ll also receive weekly updates, private deals, direct support, and private research trips all so that you can boost your revenues, expand your stock portfolio, and gain “quadruple-digit” returns.
Who Is Jeff Siegel?
According to his bio, Jeff Siegel is “an American financial writer, publisher, and musician” with a few decades of experience in the financial and stock market. He is the author of two popular books and a prominent figure in the field of renewable energy and legal cannabis investing.
Siegel is also the publisher and managing editor of Green Chip Stocks, “an independent investment research service that focuses primarily on alternative energy and transportation markets, sustainability, cannabis, and agriculture”. He is an advocate for the legalization of cannabis and has a steady base of fans and followers who trust his economic and financial expertise when it comes to future stock investment opportunities.
With restrictions regarding the consumption of mild drugs being lifted in many states across the country, investing in this sector of medicinal marijuana and cannabis could prove a good idea, at least in the short term.
However, psychedelics have a higher stigma than recreational drugs, which may cause the market in this area to develop at a slower pace than anticipated. That being said, investing in magic molecule stocks expecting high returns and “quadruple-digit” earnings in a short amount of time doesn’t seem very realistic, even if more companies seem to get on board with psychedelic drugs and more research is conducted in the field.
Given the high sensitivity of the topic and taking into account America’s current opioid crisis, fighting opioid and alcohol addiction with psychedelics may not be seen as the best option for people.
On the other hand, even though current addiction treatments and rehab facilities only have a success rate of 30-40%, the general population’s mistrust in heavier drugs, including psychedelics promoted as “magic molecules” could prove a powerful blocker of future investments in the near-term.
In other words, although investing in CBD and medicinal marijuana companies might be beneficial for your stock portfolio, the market of psychedelic drugs doesn’t seem far enough along to commercialization to offer the advertised high returns and profits of “70,000%”.
The Companies Being Teased
As with many other similar marketing letters, Siegel is trying to sell his investment program claiming he has identified three potential huge stock investment opportunities in a field named the “magic molecule” or “cannabis 2.0”.
- The first recommendation he makes is “a small company developing molecular medicine to cure opioid addiction. It’s just gone public and its stock is already up 30% proving its massive potential”. Siegel continues mentioning that “this powerhouse raised $24 million and won the backing of high-profile investors who regularly write seven-figure checks”. Also, on the day the company went public, “the stock was up 27%”.
- Combining with a quote from “one major investor” and the Kevin O’Leary reference he makes at a certain point, we were able to identify the first company being teased as Mind Medicine or MindMed (OTC: MMEDF).
- It is true that MindMed had a strong showing on its IPO day, on heavy trading volume. The company works with a series of hallucinogenic-derived drugs, including psilocybin and ibogaine.
- The second company pitched is called Captiva Verde (CSX: PWR). It mainly focuses on receiving approval for outdoor cannabis growing operations in Canada and several other deals in Mexico for marijuana cultivation. Apart from that, Captiva Verde operates businesses in Mexico that include the growth, packaging, sales, and distribution of psilocybin.
- Siegel teases gives a series of hints that made it easy for us to identify the business he was talking about, including that it has “already launched a complete production, packaging, sales, and distribution program for approximately 300 applications of the magic molecule” and that, even “though it’s still a small, young firm by most standards, over the last two years, it’s blown past the S&P 500 by almost 800%”.
- Finally, Jeff Siegel also hints to the third company with potentially high returns on the magic molecule stocks, which claims it will revolutionize plant science “with a few wellness brands, but also has branded some functional mushroom products through Neonmind Biosciences”. Although we’re not entirely sure about this third company mentioned, we could make an educated guess and name Better Plant Sciences Inc. (CSX: BOSS) as the lucky winner.
The real question is will these companies be able to stand the test of time or fall by the wayside like many of their contemporaries who have tried to build sustainable, profitable businesses in the same space?
Good Opportunity or Money Pit?
While segments such as Internet of Things, robotics, artificial intelligence, virtual reality, and cryptocurrencies may bring high returns if you are secretly psychic and can predict the breakout companies. Magic molecule companies or those that are invested in the development of hallucinogen drugs are still years away from becoming viable investment opportunities in your portfolio due in part to the country’s current opioid problem and the popularity of “orthodox” methods of curing addictions one can easily find in rehab centers.
The claims that “magic molecule” pills can cure PTSD, depression, anxiety, and addiction after just a couple of treatments are exaggerated to say the least, even though there has been encouraging results in research conducted over the years.
In other words, we’re still years away from the next big breakthrough in modern medicine and, investing in such stocks might take years for you to see any returns, let alone market beating ones simply because the market is not mature enough yet.
Judging from the product that Siegel sells, the annual subscription to his Green Chip Stocks program, paying $99 for 12 monthly newsletters, and a few extra reports on the opioid market investment opportunities seems a bit of a stretch as well. You might get a few interesting tips but, again, the psychedelic drug market will likely still take years, if not more, until it proves a profitable investment.
Quick Recap & Conclusion
- The Green Chip Stocks is an annual newsletter subscription sold and promoted by financial analyst and author Jeff Siegel. It costs $99 per year or $179 per two years and gives you access to monthly reports, as well as important investment tips, opportunities, weekly updates, direct support, and private deals in the cannabis and psychedelic drugs market.
- Siegel teases three major companies to invest in, claiming “quadruple-digit gains” if you act on the tips now on what he claims to be “the most important discovery in half a century”.
- He claims the worldwide market of these “magic molecules” will reach $2 trillion a year, without giving a prediction as to when to expect these figures to materialize.
- We identified the two stocks he was teasing, which were MindMed (OTC: MMEDF) and Captiva Verde (CSX: PWR) as well as a possible third in Better Plant Sciences Inc. (CSX: BOSS)
- Even though the research conducted so far in the field seems promising for potentially treating a series of diseases and conditions, psychedelic drugs and substances such as ibogaine and psilocybin, the market for it is still young and it may take years until the stocks you invested in will provide high returns and worth your money.
What do you think about the potential cure of some diseases and conditions, including PTSD, Alzheimer’s, diabetes, and alcoholism with the help of psychedelic drugs? What stocks if any are you watching in this emerging space?